Patents by Inventor Paul B. HARVILLA

Paul B. HARVILLA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIOENGINEERED IMMUNOMODULATORY FUSION PROTEIN COMPOSITIONS
    Publication number: 20240166720
    Abstract: Provided herein are bioengineered immunomodulatory fusion proteins and uses thereof for modulating immune responses, as well as uses for improving a response of a subject to a vaccine, or uses for treating a disease or disorder, such as cancer or a pathogen infection. Provided herein is a single chain trimeric CD40L Fc fusion protein comprising (a) three CD40 ligand CD40L subunits covalently linked to one another by peptide linkers (CD40L trimer); and (b) an Fc monomer peptide.
    Type: Application
    Filed: March 11, 2022
    Publication date: May 23, 2024
    Inventors: Ninkka TAMOT, Paul B. HARVILLA, Douglas YAMADA, Manuel Alejandro SEPULVEDA, Rajkumar GANESAN, Sanjaya SINGH
  • BIOSYNTHETIC MATERIALS AND METHODS FOR MULTIDIRECTIONAL BIOTRANSPORTATION
    Publication number: 20220112276
    Abstract: Single domain antibodies that bind to pIgR are described. The single domain antibodies may compete with IgA binding to pIgR, or alternatively, the single domain antibodies may compete with IgA binding to pIgR. The single domain antibodies may be coupled to therapeutic agents so as to facilitate delivery of the therapeutic agent to the mucosal layer via pIgR-mediated transcytosis. The therapeutic agent can be, e.g., a small molecule or large molecule such as an antibody.
    Type: Application
    Filed: October 11, 2021
    Publication date: April 14, 2022
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: Paul B. HARVILLA, Martin Jack BORROK, III, Ninkka TAMOT
  • MATERIALS AND METHODS FOR MULTIDIRECTIONAL BIOTRANSPORTATION IN VIROTHERAPEUTICS
    Publication number: 20220033522
    Abstract: Provided herein are multispecific molecules comprising a first binding domain that specifically binds to polymeric immunoglobulin receptor (pIgR) and a second binding domain that specifically binds to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and related methods for the treatment of patients infected with SARS-CoV-2.
    Type: Application
    Filed: August 2, 2021
    Publication date: February 3, 2022
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: Rajkumar GANESAN, Adam ZWOLAK, Ian WHITE, Ninkka TAMOT, Paul B. HARVILLA, Rajitha DODDAREDDY, Sanjaya SINGH, Martin Jack BORROK III